Your browser doesn't support javascript.
loading
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia.
Ge, Maolin; Qiao, Zhi; Kong, Yan; Lu, Hui; Liu, Han.
Afiliação
  • Ge M; State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Qiao Z; State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Kong Y; SJTU-Yale Joint Center for Biostatistics, Shanghai Jiao Tong University, Shanghai, China.
  • Lu H; SJTU-Yale Joint Center for Biostatistics, Shanghai Jiao Tong University, Shanghai, China.
  • Liu H; State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Cancer Sci ; 111(4): 1279-1290, 2020 Apr.
Article em En | MEDLINE | ID: mdl-32058648
ABSTRACT
Proteasome inhibitors significantly improve cancer outcomes, but their use is eventually followed by proteasome inhibitor resistance and relapse. Current understanding of proteasome inhibitor resistance is limited to cell-autonomous mechanisms; whether non-autonomous mechanisms can be implicated in the development of proteasome inhibitor resistance is unclear. Here, we show that proteasome inhibitor tolerance can be transmitted non-autonomously through exosome-mediated intercellular interactions. We revealed that reversible proteasome inhibitor resistance can be transmitted from cells under therapy stress to naïve sensitive cells through exosome-mediated cell cycle arrest and enhanced stemness in mixed-lineage leukemia cells. Integrated multi-omics analysis using the Tied Diffusion through Interacting Events algorithm identified several candidate exosomal proteins that may serve as predictors for proteasome inhibitor resistance and potential therapeutic targets for treating refractory mixed-lineage leukemia. Furthermore, inhibiting the secretion of exosomes is a promising strategy for reversing proteasome inhibitor resistance in vivo, which provides a novel proof of principle for the treatment of other refractory or relapsed cancers.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Aguda Bifenotípica / Complexo de Endopeptidases do Proteassoma / Inibidores de Proteassoma / Tolerância Imunológica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Aguda Bifenotípica / Complexo de Endopeptidases do Proteassoma / Inibidores de Proteassoma / Tolerância Imunológica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China